Search research articles
Contact Us
Filters
Showing results (21-30 of 120) with videos related to
Page
of 12
Sort By:
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration
|
February 7, 2018
VITALITY-ALS, a phase III trial of tirasemtiv, a selective fast skeletal muscle troponin activator, as a potential treatment for patients with amyotrophic lateral sclerosis: study design and baseline characteristics
Jinsy A Andrews, Merit E Cudkowicz, Orla Hardiman, et al.
Muscle & Nerve
|
March 21, 2013
Fast skeletal muscle troponin activator in the dy2J muscular dystrophy model
Jessica J Miciak, Leigh C Warsing, Maria E Tibbs, et al.
JAMA Neurology
|
November 29, 2017
Association Between Decline in Slow Vital Capacity and Respiratory Insufficiency, Use of Assisted Ventilation, Tracheostomy, or Death in Patients With Amyotrophic Lateral Sclerosis
Jinsy A Andrews, Lisa Meng, Sarah F Kulke, et al.
Health and Quality of Life Outcomes
|
September 16, 2016
Incorporating development of a patient-reported outcome instrument in a clinical drug development program: examples from a heart failure program
Ingela Wiklund, Milena Anatchkova, Hafiz Oko-Osi, et al.
Plos One
|
May 9, 2014
Fast skeletal muscle troponin activator tirasemtiv increases muscle function and performance in the B6SJL-SOD1G93A ALS mouse model
Darren T Hwee, Adam Kennedy, Julie Ryans, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
July 26, 2011
Inhibition of smooth muscle myosin as a novel therapeutic target for hypertension
Xin Zhao, David Ho, Patricio Abarzúa, et al.
Plos One
|
May 8, 2012
Smooth muscle myosin inhibition: a novel therapeutic approach for pulmonary hypertension
David Ho, Li Chen, Xin Zhao, et al.
JACC. Heart Failure
|
July 11, 2016
Patient-Reported Outcomes in Chronic Heart Failure: Applicability for Regulatory Approval
Mitchell A Psotka, Robyn von Maltzahn, Milena Anatchkova, et al.
The Journal of Physiology
|
November 22, 2016
The Ca<sup>2+</sup> sensitizer CK-2066260 increases myofibrillar Ca<sup>2+</sup> sensitivity and submaximal force selectively in fast skeletal muscle
Darren T Hwee, Arthur J Cheng, James J Hartman, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration
|
April 1, 2021
Noninvasive ventilation use by patients enrolled in VITALITY-ALS
Stacy A Rudnicki, Jinsy A Andrews, Amy Bian, et al.
Page
of 12
Search research articles
Search
Showing results (21-30 of 120) with videos related to
Sort By:
Page
of 12
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration
|
February 7, 2018
VITALITY-ALS, a phase III trial of tirasemtiv, a selective fast skeletal muscle troponin activator, as a potential treatment for patients with amyotrophic lateral sclerosis: study design and baseline characteristics
Jinsy A Andrews, Merit E Cudkowicz, Orla Hardiman, et al.
Muscle & Nerve
|
March 21, 2013
Fast skeletal muscle troponin activator in the dy2J muscular dystrophy model
Jessica J Miciak, Leigh C Warsing, Maria E Tibbs, et al.
JAMA Neurology
|
November 29, 2017
Association Between Decline in Slow Vital Capacity and Respiratory Insufficiency, Use of Assisted Ventilation, Tracheostomy, or Death in Patients With Amyotrophic Lateral Sclerosis
Jinsy A Andrews, Lisa Meng, Sarah F Kulke, et al.
Health and Quality of Life Outcomes
|
September 16, 2016
Incorporating development of a patient-reported outcome instrument in a clinical drug development program: examples from a heart failure program
Ingela Wiklund, Milena Anatchkova, Hafiz Oko-Osi, et al.
Plos One
|
May 9, 2014
Fast skeletal muscle troponin activator tirasemtiv increases muscle function and performance in the B6SJL-SOD1G93A ALS mouse model
Darren T Hwee, Adam Kennedy, Julie Ryans, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
July 26, 2011
Inhibition of smooth muscle myosin as a novel therapeutic target for hypertension
Xin Zhao, David Ho, Patricio Abarzúa, et al.
Plos One
|
May 8, 2012
Smooth muscle myosin inhibition: a novel therapeutic approach for pulmonary hypertension
David Ho, Li Chen, Xin Zhao, et al.
JACC. Heart Failure
|
July 11, 2016
Patient-Reported Outcomes in Chronic Heart Failure: Applicability for Regulatory Approval
Mitchell A Psotka, Robyn von Maltzahn, Milena Anatchkova, et al.
The Journal of Physiology
|
November 22, 2016
The Ca<sup>2+</sup> sensitizer CK-2066260 increases myofibrillar Ca<sup>2+</sup> sensitivity and submaximal force selectively in fast skeletal muscle
Darren T Hwee, Arthur J Cheng, James J Hartman, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration
|
April 1, 2021
Noninvasive ventilation use by patients enrolled in VITALITY-ALS
Stacy A Rudnicki, Jinsy A Andrews, Amy Bian, et al.
Page
of 12